Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study
Sign Up to like & getrecommendations! Published in 2021 at "International Journal of Infectious Diseases"
DOI: 10.1016/j.ijid.2021.03.015
Abstract: Objective To evaluate the efficacy and safety of pegylated interferon alfa-2b (PEG IFN-α2b) along with the standard of care (SOC) in subjects with moderate COVID-19. Methods In this phase 2, randomized, open-label study, adult subjects… read more here.
Keywords: ifn plus; moderate covid; plus soc; day ... See more keywords
Treatment Response to Esketamine Nasal Spray in Patients With Major Depressive Disorder and Acute Suicidal Ideation or Behavior Without Evidence of Early Response: A Pooled Post Hoc Analysis of ASPIRE.
Sign Up to like & getrecommendations! Published in 2022 at "CNS spectrums"
DOI: 10.1017/s1092852922000931
Abstract: Objective. To assess the likelihood of attaining response/remission of depressive symptoms withesketamine nasalspray (ESK) plusstandard ofcare (SoC) vsplacebo nasal spray (PBO)plus SoCat 4weeks in patients withmajor depressive disorder and active suicidal ideation withintent (MDSI) without… read more here.
Keywords: plus soc; pbo; response remission; remission ... See more keywords
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial
Sign Up to like & getrecommendations! Published in 2024 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2023-008409
Abstract: Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with standard therapies in patients with mCRC. Here,… read more here.
Keywords: plus soc; checkmate 9x8; nivolumab plus; first line ... See more keywords